Cargando…

Combining CSPG4-CAR and CD20-CCR for treatment of metastatic melanoma

The prognosis for patients with metastatic melanoma is poor and treatment options are limited. Genetically-engineered T cell therapy targeting chondroitin sulfate proteoglycan 4 (CSPG4), however, represents a promising treatment option, especially as both primary melanoma cells as well as metastases...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teppert, Karin, Winter, Nora, Herbel, Vera, Brandes, Caroline, Lennartz, Simon, Engert, Fabian, Kaiser, Andrew, Schaser, Thomas, Lock, Dominik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603253/ https://www.ncbi.nlm.nih.gov/pubmed/37901209 http://dx.doi.org/10.3389/fimmu.2023.1178060

Ejemplares similares

Automated, scaled, transposon-based production of CAR T cells
por: Lock, Dominik, et al.
Publicado: (2022)

Combined targeting of soluble latent TGF-ß and a solid tumor-associated antigen with adapter CAR T cells
por: Werchau, Niels, et al.
Publicado: (2022)

Joining Forces for Cancer Treatment: From “TCR versus CAR” to “TCR and CAR”
por: Teppert, Karin, et al.
Publicado: (2022)

Automated generation of gene-edited CAR T cells at clinical scale
por: Alzubi, Jamal, et al.
Publicado: (2020)

Decitabine-Mediated Upregulation of CSPG4 in Ovarian Carcinoma Cells Enables Targeting by CSPG4-Specific CAR-T Cells
por: Harrer, Dennis Christoph, et al.
Publicado: (2022)

Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance
por: Wiesinger, Manuel, et al.
Publicado: (2019)

CSPG4 as Target for CAR-T-Cell Therapy of Various Tumor Entities–Merits and Challenges
por: Harrer, Dennis C., et al.
Publicado: (2019)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

CSPG4-Specific CAR T Cells for High-Risk Childhood B Cell Precursor Leukemia
por: Harrer, Dennis C., et al.
Publicado: (2019)

Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF
por: Uranowska, Karolina, et al.
Publicado: (2021)

Targeting the melanoma-associated antigen CSPG4 with HLA-C*07:01-restricted T-cell receptors
por: Kropp, Korbinian N., et al.
Publicado: (2023)

The regulatory mechanisms of NG2/CSPG4 expression
por: Ampofo, Emmanuel, et al.
Publicado: (2017)

Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma
por: Wang, Jian, et al.
Publicado: (2011)

Titratable Pharmacological Regulation of CAR T Cells Using Zinc Finger-Based Transcription Factors
por: Kotter, Bettina, et al.
Publicado: (2021)

Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells
por: Cordes, Nicole, et al.
Publicado: (2021)

Antigen mimicry as an effective strategy to induce CSPG4-targeted immunity in dogs with oral melanoma: a veterinary trial
por: Riccardo, Federica, et al.
Publicado: (2022)

Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
por: Nicolosi, Pier Andrea, et al.
Publicado: (2015)

Localization and Developmental Expression Patterns of CSPG in the RCS Rat Retina
por: Chen, Li-Feng, et al.
Publicado: (2011)

CSPG4: a prototype oncoantigen for translational immunotherapy studies
por: Rolih, Valeria, et al.
Publicado: (2017)

Cspg4(high) microglia contribute to microgliosis during neurodegeneration
por: Liu, Ya-jing, et al.
Publicado: (2023)

Arming T Cells with a gp100-Specific TCR and a CSPG4-Specific CAR Using Combined DNA- and RNA-Based Receptor Transfer
por: Simon, Bianca, et al.
Publicado: (2019)

Targeting Stage-Specific Embryonic Antigen 4 (SSEA-4) in Triple Negative Breast Cancer by CAR T Cells Results in Unexpected on Target/off Tumor Toxicities in Mice
por: Pfeifer, Rita, et al.
Publicado: (2023)

The Significance of Chondroitin Sulfate Proteoglycan 4 (CSPG4) in Human Gliomas
por: Schiffer, Davide, et al.
Publicado: (2018)

Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers
por: Zhang, Hongyu, et al.
Publicado: (2022)

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Identification of CSPG4 as a promising target for translational combinatorial approaches in osteosarcoma
por: Riccardo, Federica, et al.
Publicado: (2019)

NG2/CSPG4 regulates cartilage degeneration during TMJ osteoarthritis
por: Reed, David A., et al.
Publicado: (2022)

Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma
por: Schäfer, Daniel, et al.
Publicado: (2021)

Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting
por: Seitz, Christian M., et al.
Publicado: (2021)

A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Two PTP receptors mediate CSPG inhibition by convergent and divergent signaling pathways in neurons
por: Ohtake, Yosuke, et al.
Publicado: (2016)

CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
por: Jordaan, Sandra, et al.
Publicado: (2017)

Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells
por: Wang, Chris Kedong, et al.
Publicado: (2022)

CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
por: de Nonneville, Alexandre, et al.
Publicado: (2022)

Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B
por: Feigl, Frederik Fabian, et al.
Publicado: (2023)

Chondroitin Sulfate Proteoglycan CSPG4 as a Novel Hypoxia-Sensitive Marker in Pancreatic Tumors
por: Keleg, Shereen, et al.
Publicado: (2014)

Impact of KMT2A Rearrangement and CSPG4 Expression in Pediatric Acute Myeloid Leukemia
por: Hoffmeister, Lina Marie, et al.
Publicado: (2021)

NG2/CSPG4 attenuates motility in mandibular fibrochondrocytes under serum starvation conditions
por: Ahn, Shin Young, et al.
Publicado: (2023)

The CCL20-CCR6 Axis in Cancer Progression
por: Kadomoto, Suguru, et al.
Publicado: (2020)

CCR4 is a determinant of melanoma brain metastasis
por: Klein, Anat, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bo7o2t6p3kp2lkqlnif5r3co9g